Orders of the Products Sample Clauses

Orders of the Products. 3.1 Each sale of Product(s) shall be conditional on the submission by Distributor to Manufacturer of a written order. No order shall be binding on Manufacturer until such order has been accepted by Manufacturer in writing. 3.2 During the term of this Agreement, Distributor hereby undertakes to purchase Products from Manufacturer for a total quantity of no less than (the “ Minimum Purchase”). Minimum Quantity per year will be [***] implants. The minimum value of distributor’s purchase per order is Euro [***] 3.3 In addition to the Minimum purchase, Distributor will order Implants for the courses he conducts in his training center. Upon providing the Manufacturer with the course participants list and the estimated purchase quantity of each participant, the Distributor will receive a special purchase price of Euro [***] for each implant up to [***] implants per year.
AutoNDA by SimpleDocs
Orders of the Products. 3.1 Each sale of Product(s) shall be conditional on the submission by Distributor to Manufacturer of a written order. No order shall be binding on Manufacturer until such order has been accepted by Manufacturer in writing. Such accepted order should be delivered to the Distributor within 21 days from receiving the payment for the entire order value from the Distributor. The Manufacturer shall bear no responsibility for the delay of cargo on the territory of the Russian Federation. 3.2 During the term of this Agreement Distributor hereby undertakes to purchase Products and services from Manufacturer for a total Yearly amount of no less than (the “Yearly Minimum Purchase”). [***] Within any specific year, excess in the quarterly purchased amount could be subtracted from the following quarter minimum amount as long as the Yearly minimum purchase amount is achieved. 3.3 [***] 3.4 Subject to the distributor obligation for the minimum orders and agreed yearly marketing plan, Manufacturer shall participate in and support to the marketing expenses of the Distributor as agreed in the marketing plan detailed in Exhibit “B” attached hereto (“support Plan”).
Orders of the Products. 3.1 Each sale of Product(s) shall be conditional on the submission by Distributor to Manufacturer of a written order. Manufacturer may accept or refuse any order, in whole or in part, at its sole discretion. No order shall be binding on Manufacturer until such order has been accepted by Manufacturer in writing. 3.2 Distributor obligation to buy from the Manufacturer: 3.2.1 [***] inventory order 30 working days from regulation approval in the territory. 3.2.2 Minimum quantity in 2019, [***] units of implants. 3.2.3 Minimum quantity in 2020, [***] units of implants. 3.2.4 Minimum quantity in 2021, [***] units of implants. 3.2.5 Minimum quantity in 2022, [***] units of implants. From the beginning of the 5th year onwards, Distributor expected an increase of 15% in annual purchases. 3.3 Subject to the distributor obligation for the minimum orders and agreed yearly marketing plan, Manufacturer shall participate in and support to the marketing expenses of the Distributor as agreed in the marketing plan detailed in Exhibit “B” attached hereto (“Promotional support”).
Orders of the Products. 3.1 Each sale of Product(s) shall be conditional on the submission by Distributor to Manufacturer of a written order. Manufacturer may accept or refuse any order, in whole or in part, at its sole discretion. No order shall be binding on Manufacturer until such order has been accepted by Manufacturer in writing. Products dispatched should have a minimum of 3 years shelf-life. 3.2 Distributor obligation to buy from the Manufacturer: [***] inventory will be ordered in 30 working days from signing this agreement. In the case, the Distributor buys Products from the previous distributor, that will be deducted from this amount. In case of excess, against future orders.
Orders of the Products 

Related to Orders of the Products

  • Products Products available under this Contract are limited to Software, including Software as a Service, products and related products as specified in Appendix C, Pricing Index. Vendor may incorporate changes to their product offering; however, any changes must be within the scope of products awarded based on the posting described in Section 1.B above. Vendor may not add a manufacturer’s product line which was not included in the Vendor’s response to the solicitation described in Section 1.B above.

  • Licensed Products Lessee will obtain no title to Licensed Products which will at all times remain the property of the owner of the Licensed Products. A license from the owner may be required and it is Lessee's responsibility to obtain any required license before the use of the Licensed Products. Lessee agrees to treat the Licensed Products as confidential information of the owner, to observe all copyright restrictions, and not to reproduce or sell the Licensed Products.

  • Medications Psychotropic medications and medications associated with treating a diagnosed mental health condition.

  • New Products You agree to comply with NASD Notice to Members 5-26 recommending best practices for reviewing new products.

  • Labeling Upon request, Lessee will xxxx the Equipment indicating Lessor's interest with labels provided by Lessor. Lessee will keep all Equipment free from any other marking or labeling which might be interpreted as a claim of ownership.

  • Product Labeling The labeling of all Licensed Products sold or offered for sale under this Agreement shall expressly state that the Licensed Product is manufactured under a license from the Medicines Patent Pool.

  • Manufacture of Products All Products marketed through Grantor's Web ------------------------- Site shall be manufactured, packaged, prepared, and shipped in accordance with the specifications and requirements described on Exhibit A hereto as it may be modified from time to time. Quality control standards relating to the Product's weight, color, consistency, micro-biological content, labeling and packaging are also set forth on Exhibit A. In the event that Exhibit A is incomplete, Products shall be manufactured and shipped in accordance with industry standards.

  • Regulatory Authorities Except as described in the Registration Statement, the General Disclosure Package or the Prospectus, each of the Company and its subsidiaries: (a) is and at all times has been in material compliance with all statutes, rules or regulations applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product manufactured or distributed by the Company (“Applicable Laws”); (b) has not received any FDA Form 483, notice of adverse finding, warning letter, untitled letter or other correspondence or notice from the FDA or any other federal, state or foreign governmental authority having authority over the Company (“Governmental Authority”) alleging or asserting material noncompliance with any Applicable Laws or any licenses, certificates, approvals, clearances, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws (“Authorizations”); (c) possesses all Authorizations and such Authorizations are valid and in full force and effect and are not in material violation of any term of any such Authorizations; (d) has not received notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any Governmental Authority or third party alleging that any product, operation or activity is in violation of any Applicable Laws or Authorizations and have no knowledge that any such Governmental Authority or third party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding; (e) has not received notice that any Governmental Authority has taken, is taking or intends to take action to limit, suspend, modify or revoke any Authorizations and has no knowledge that any such Governmental Authority is considering such action; and (f) has filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were materially complete and correct on the date filed (or were corrected or supplemented by a subsequent submission). The studies, tests and preclinical and clinical trials material to the Company and its subsidiaries taken as a whole, and conducted by or on behalf of the Company and each of its subsidiaries, were and, if still pending, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all Applicable Laws and Authorizations, including, without limitation, the Federal Food, Drug and Cosmetic Act and implementing regulations at 21 C.F.R. Parts 50, 54, 56, 58 and 312; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the General Disclosure Package or the Prospectus are accurate and complete in all material respects and fairly present the data derived from such studies, tests and trials; except to the extent disclosed in the Registration Statement, the General Disclosure Package or the Prospectus, the Company is not aware of any studies, tests or trials the results of which the Company believes reasonably call into question the study, test, or trial results described or referred to in the Registration Statement, the General Disclosure Package or the Prospectus when viewed in the context in which such results are described and the clinical state of development; and neither the Company nor any of its subsidiaries has received any notices or correspondence from any Governmental Authority requiring the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company or any of its subsidiaries that are material to the Company and its subsidiaries taken as a whole.

  • Existing Products Except as set forth below, Contractor shall retain all rights, title and interest in Existing Products.

  • Product ACCEPTANCE Unless otherwise provided by mutual agreement of the Authorized User and the Contractor, Authorized User(s) shall have thirty (30) days from the date of delivery to accept hardware products and sixty (60) days from the date of delivery to accept all other Product. Where the Contractor is responsible for installation, acceptance shall be from completion of installation. Failure to provide notice of acceptance or rejection or a deficiency statement to the Contractor by the end of the period provided for under this clause constitutes acceptance by the Authorized User(s) as of the expiration of that period. The License Term shall be extended by the time periods allowed for trial use, testing and acceptance unless the Commissioner or Authorized User agrees to accept the Product at completion of trial use. Unless otherwise provided by mutual agreement of the Authorized User and the Contractor, Authorized User shall have the option to run testing on the Product prior to acceptance, such tests and data sets to be specified by User. Where using its own data or tests, Authorized User must have the tests or representative set of data available upon delivery. This demonstration will take the form of a documented installation test, capable of observation by the Authorized User, and shall be made part of the Contractor’s standard documentation. The test data shall remain accessible to the Authorized User after completion of the test. In the event that the documented installation test cannot be completed successfully within the specified acceptance period, and the Contractor or Product is responsible for the delay, Authorized User shall have the option to cancel the order in whole or in part, or to extend the testing period for an additional thirty (30) day increment. Authorized User shall notify Contractor of acceptance upon successful completion of the documented installation test. Such cancellation shall not give rise to any cause of action against the Authorized User for damages, loss of profits, expenses, or other remuneration of any kind. If the Authorized User elects to provide a deficiency statement specifying how the Product fails to meet the specifications within the testing period, Contractor shall have thirty (30) days to correct the deficiency, and the Authorized User shall have an additional sixty (60) days to evaluate the Product as provided herein. If the Product does not meet the specifications at the end of the extended testing period, Authorized User, upon prior written notice to Contractor, may then reject the Product and return all defective Product to Contractor, and Contractor shall refund any monies paid by the Authorized User to Contractor therefor. Costs and liabilities associated with a failure of the Product to perform in accordance with the functionality tests or product specifications during the acceptance period shall be borne fully by Contractor to the extent that said costs or liabilities shall not have been caused by negligent or willful acts or omissions of the Authorized User’s agents or employees. Said costs shall be limited to the amounts set forth in the Limitation of Liability Clause for any liability for costs incurred at the direction or recommendation of Contractor.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!